Masao Tomonaga
Hamamatsu University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Masao Tomonaga.
Journal of Clinical Oncology | 1997
Ryuzo Ohno; Shuichi Miyawaki; Kiyohiko Hatake; Kazutaka Kuriyama; Kenji Saito; Akihisa Kanamaru; Tohru Kobayashi; Yoshihisa Kodera; Kiyoshi Nishikawa; Shin Matsuda; Osamu Yamada; Eijiro Omoto; Hideo Takeyama; Koji Tsukuda; Norio Asou; Mitsune Tanimoto; Hiroko Shiozaki; Masao Tomonaga; Tohru Masaoka; Yasusada Miura; Fumimaro Takaku; Yasuo Ohashi; Kazuo Motoyoshi
PURPOSE To determine whether macrophage colony-stimulating factor (M-CSF) reduces the incidence and duration of febrile neutropenia during three courses of intensive consolidation therapy and whether it shortens time to complete consolidation therapy. PATIENTS AND METHODS In 198 adult patients with acute myeloid leukemia (AML) in complete remission (CR), M-CSF (8 x 10(6) U/d) or placebo was administered from 1 day after the end of each consolidation chemotherapy for 14 days. RESULTS The duration and incidence of febrile neutropenia was significantly reduced by 34% (P = .00285) and 17% (P = .02065), respectively, in 88 assessable patients in the M-CSF group compared with those in 94 assessable patients in the placebo group. Patients in the M-CSF group had 565 days and 133 episodes of febrile neutropenia during 7,901 days at risk, while patients in the placebo group had 977 days and 185 episodes during 9,077 days at risk. The median period required to finish the three courses of consolidation therapy was 93 days in the M-CSF group, which was significantly shorter than 110 days in placebo group (P = .0050). In the M-CSF group, the recovery of neutrophils and platelets was significantly faster (P = .0348 and P = 0.0364, respectively), the administration of systemic antimicrobial agents tended to be less (P = .0839), and the frequency of platelet transfusion (P = .0259) and the total volume of transfused platelets (P = .0292) were significantly less. However, there was no significant difference in the disease-free survival. CONCLUSION M-CSF significantly reduced the incidence and duration of febrile neutropenia during the intensive consolidation therapy, and shortened the time to complete consolidation chemotherapy in AML.
Mayo Clinic proceedings | 2008
Guillermo J. Ruiz-Delgado; Guillermo J. Ruiz-Argüelles; Ola Landgren; Lynn R. Goldin; Neil E. Caporaso; Robert A. Kyle; S. Vincent Rajkumar; Masako Iwanaga; Kunihiro Tsukasaki; Shimeru Kamihira; Masao Tomonaga
Acta medica Nagasakiensia | 1990
Masao Tomonaga; Tomoko Kohno; Kazutaka Kuriyama; Masuko Tagawa; Itsuro Jinnai; Yoshiharu Yoshida; Hiroaki Nonaka; Michito Ichimaru
Archive | 2013
Masao Tomonaga; Manuel Aivado; Masako Iwanaga; Yasushi Miyazaki; Hideki Tsushima; Mari Sakai; Masami Bessho; Akira Matsuda; Ulrich Germing; Itsuro Jinnai; Motohiro Misumi; Andrea Kuendgen; S. Knipp
Archive | 2011
Sabro Momita; Shimeru Kamihira; Masao Tomonaga; Takuya Fukushima; Tomoko Hata; Yoshitaka Imaizumi; Daisuke Imanishi; Jun Taguchi; Masako Iwanaga; Masuko Tagawa; Kunihiro Tsukasaki; Tatsuki Matsuo; Kenichi Yokota
Archive | 2010
Masao Tomonaga; Naoki Yamamoto; Masahiro Fujii; Naoki Mori; Yasuaki Yamada; Shuichi Ikeda; Yoshihiro Yamasaki; Kunihiro Tsukasaki; Yuetsu Tanaka
Cytometry research : 日本サイトメトリー学会機関誌 | 2004
Kazuhiro Nagai; Kazuto Tsuruda; Yasushi Miyazaki; Itsurou Jinnai; Kazutaka Kuriyama; Shimeru Kamihira; Masao Tomonaga
Acta medica Nagasakiensia | 1997
Masao Tomonaga; Tatsuki Matsuo; Johnm. Bennett
Acta medica Nagasakiensia | 1990
Tatsuki Matsuo; Masao Tomonaga; Itsuro Jinnai; Kazutaka Kuriyama; Tatsuhiko Amenomori; Yoshiharu Yoshida; Michito Ichimaru; Davidw. Golde
Acta medica Nagasakiensia | 1990
Masao Tomonaga; Itsuro Jinnai; Tatsuhiko Amenomori; Hiroaki Matsuo; Yoshiharu Yoshida; Kazutaka Kuriyama; Michito Ichimaru